计算生物学模型预测新诊断胶质母细胞瘤放化疗结局
这项回顾性单中心研究纳入98例接受手术、放疗和替莫唑胺治疗的新诊断胶质母细胞瘤患者,用基因组信息驱动的计算生物学模型预测放疗和替莫唑胺疗效。高放疗疗效评分与更长生存相关,多因素校正后仍显著;高替莫唑胺疗效评分单因素与生存相关但多因素不显著。模型还为每例患者生成个体化治疗建议,其中仅2.4%的两药推荐包含替莫唑胺。
要点
- 高RTeff评分与更长总生存相关,多因素校正后仍显著。
- 高RTeff患者中位总生存27.7个月,低RTeff为14.6个月。
- 高TMZeff单因素与生存相关,多因素校正后不显著。
核心结论
- 基于计算生物学模型的放疗和替莫唑胺疗效预测与新诊断胶质母细胞瘤患者生存相关,提示可能具有预测价值。
- 模型可提出新的个体化单药和联合治疗建议,但需前瞻性临床试验验证。
研究设计与样本
- 回顾性单中心研究,纳入98例接受手术、放疗和替莫唑胺治疗且有基因组数据的新诊断胶质母细胞瘤患者。
- 利用突变和拷贝数畸变数据,计算生物学模型模拟肿瘤细胞反应,生成RTeff和TMZeff评分。
- 采用Cox回归模型评估RTeff和TMZeff与总生存和无进展生存的关联。
- 通过测试45种中枢神经系统穿透性美国食品药品监督管理局批准药物,为每例患者生成治疗建议。
主要发现
- 高RTeff评分与更长生存相关(单因素P < .001),校正年龄、切除程度、体能状态、MGMT和IDH状态后仍显著(P = .017)。
- 高RTeff患者中位总生存27.7个月,低RTeff患者为14.6个月。
- 高TMZeff评分单因素与更长生存相关(P = .007),但多因素分析不显著,提示与MGMT状态存在交互作用。
- 在每例患者3种最有效联合治疗预测中,294个两药推荐里仅7个(2.4%)包含替莫唑胺。
临床怎么用
- 该模型可能辅助筛选放疗和替莫唑胺获益人群,但当前证据为回顾性,尚不能直接用于临床决策。
- 模型生成的个体化单药或联合治疗建议需在前瞻性临床试验中验证。
局限性
- 回顾性单中心研究,样本量98例,结论需外部验证。
- 模型预测的个体化治疗建议尚未经前瞻性临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Precision medicine has been most successful in targeting single mutations, but personalized medicine using broader genomic tumor profiles for individual patients is less well developed. We evaluate a genomics-informed computational biology model (CBM) to predict outcomes from standard treatments and to suggest novel therapy recommendations in glioblastoma (GBM). METHODS AND MATERIALS: In this retrospective study, 98 patients with newly diagnosed GBM undergoing surgery followed by radiation therapy and temozolomide at a single institution with available genomic data were identified. Incorporating mutational and copy number aberration data, a CBM was used to simulate the response of GBM tumor cells and generate efficacy predictions for radiation therapy (RTeff) and temozolomide (TMZeff). RTeff and TMZeff were evaluated for association with overall survival and progression-free survival in a Cox regression model. To demonstrate a CBM-based individualized therapy strategy, treatment recommendations were generated for each patient by testing a panel of 45 central nervous system-penetrant US Food and Drug Administration-approved agents. RESULTS: High RTeff scores were associated with longer survival on univariable analysis (P < .001), which persisted after controlling for age, extent of resection, performance status, MGMT, and IDH status (P = .017). High RTeff patients had a longer overall survival compared with low RTeff patients (median, 27.7 vs 14.6 months). High TMZeff was also associated with longer survival on univariable analysis (P = .007) but did not hold on multivariable analysis, suggesting an interplay with MGMT status. Among predictions of the 3 most efficacious combination therapies for each patient, only 2.4% (7 of 294) of 2-drug recommendations produced by the CBM included TMZ. CONCLUSIONS: CBM-based predictions of RT and TMZ effectiveness were associated with survival in patients with newly diagnosed GBM treated with those therapies, suggesting a possible predictive utility. Furthermore, the model was able to suggest novel individualized monotherapies and combinations. Prospective evaluation of such a personalized treatment strategy in clinical trials is needed.
引用
- Rahman R, Trippa L, Alden S, et al. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020. PMID: 32417407. doi:10.1016/j.ijrobp.2020.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。